title: Fibrate therapy in the management of dyslipidemias, alone and in combination with statins: role of delayed-release fenofibric acid.
abstract: BACKGROUND
  Optimization of lipid management is a crucial aspect in the treatment of cardiovascular disease. Currently, HMG-CO reductase inhibitors (statins) are a mainstay of therapy. While this class of drugs has proven efficacy at lowering low-density lipoprotein cholesterol (LDL-C), their effects on other important lipid parameters, such as high-density lipoprotein cholesterol (HDL-C) and triglycerides, are less robust.
  
  
  METHODS
  The current paper will address the significance of these secondary targets and review currently available therapies, including a new formulation of delayed-release fenofibric acid. A comprehensive MEDLINE search (1966 to September 2009) was performed.
  
  
  RESULTS
  The reader will gain a comprehensive review of the importance of secondary cholesterol targets, as well as the effectiveness of currently available therapies to address non-LDL-C. The role of the newly released fenofibric acid will also be addressed, as well as its potential use in combination therapy with a statin.
  
  
  CONCLUSIONS
  Adequate treatment of lipid parameters beyond LDL-C is an essential component in the treatment of dyslipidemia. The fibrate class of drugs has proven efficacy in improving secondary targets; however, concerns regarding severe myopathy and rhabdomyolysis have limited their combination with statins. Recently, a new fibrate derivative, fenofibric acid, has become available. Studies to date reflect a positive safety and tolerability profile when combined with statins. This may offer a new tool to address the important secondary cholesterol targets that are becoming increasingly recognized as important contributors to cardiovascular outcomes.
authors.affiliation: Department of Medicine, Division of Cardiology, Creighton University School of Medicine, Omaha, NE 68131, USA. Susan.Schima@cardiac.creighton.edu
authors.forename: Susan M
authors.initials: SM
authors.lastname: Schima
authors.forename: Stephanie R
authors.initials: SR
authors.lastname: Maciejewski
authors.forename: Daniel E
authors.initials: DE
authors.lastname: Hilleman
authors.forename: Mark A
authors.initials: MA
authors.lastname: Williams
authors.forename: Syed M
authors.initials: SM
authors.lastname: Mohiuddin
mesh_terms: D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control*; D008078:Cholesterol, LDL / Q000097:blood / Q000187:drug effects; D003692:Delayed-Action Preparations; D016503:Drug Delivery Systems; D050171:Dyslipidemias / Q000150:complications / Q000188:drug therapy*; D011345:Fenofibrate / Q000009:adverse effects / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D008078:Cholesterol, LDL; D003692:Delayed-Action Preparations; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; C006012:fenofibric acid; D011345:Fenofibrate